[REVISION HISTORY]

MannKind Furoscix ReadyFlow approval

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-07-29 16:21 UTC → 2026-07-29 23:50 UTC · added ~~removed~~

MannKind Corporation secured a $50 million private placement and received FDA approval for its Furoscix ReadyFlow auto‑injector in late July 2026. The financing, led by Frazier Life Sciences, will fund general corporate purposes and includes a $45 million contingent‑value‑rights payment linked to regulatory clearance. The FDA cleared the sub‑cutaneous device, which delivers an 80 mg/mL dose of furosemide in under 10 seconds, offering an at‑home alternative to IV therapy for adults with heart failure or chronic kidney disease. ~~The company plans a U.S. commercial launch by August 2026, with the product expected to reach pharmacies by the end of that month.~~ Clinical data from a trial of 21 healthy volunteers showed urine ~~output~~ output, sodium and ~~electrolyte~~ potassium excretion comparable to standard IV ~~treatment. A peripheral mention of a Taiwanese blood‑based TB biosensor appeared~~ furosemide at 6, 8 and 12 hours, with bioavailability around 107 % and safety limited to local injection‑site reactions and expected systemic effects. MannKind expects commercial availability in the ~~same release, but the core development remains~~ United States by the ~~approval~~ end of August 2026 and ~~financing~~ plans pharmacy distribution shortly thereafter. The company also announced the acquisition of scPharmaceuticals for up to $360 million, expanding its pipeline beyond the Furoscix ~~ReadyFlow system.~~ platform.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.